Quercetin targets `IGF1` signaling, downregulating `IGF1` mRNA and inhibiting activity in gastric cancer cells
Background
Gastric cancer (GC) remains a leading cause of cancer-related mortality globally, with current therapies often limited by drug resistance and systemic toxicity. This highlights an urgent need for novel, less toxic therapeutic strategies. The insulin-like growth factor 1 (IGF1) signaling pathway is a critical driver of cancer cell proliferation, survival, and metastasis in many malignancies, including GC. However, the specific molecular mechanisms by which natural compounds like Quercetin might modulate this key pathway in GC have remained largely unexplored, representing a significant gap in targeted therapeutic development.
Study Design
Researchers employed a multi-faceted approach, combining computational and in vitro methods to investigate Quercetin's anticancer potential. Network pharmacology analysis identified potential GC-related targets. Molecular docking and 200 ns molecular dynamics (MD) simulations were then used to evaluate the binding affinity and stability of the Quercetin-target complex. For in vitro validation, AGS gastric cancer cells were utilized for gene expression analysis (qPCR) and fluorescence binding assays to confirm the computational findings regarding IGF1 modulation.
Results
Network pharmacology analysis identified IGF1 as a key hub gene critically associated with gastric cancer progression. Molecular docking predicted a favorable interaction between Quercetin and IGF1, yielding a docking score of -6.3 kcal/mol and demonstrating multiple hydrogen-bond interactions. MD simulations further confirmed the stability of the Quercetin-IGF1 complex, showing significantly reduced RMSD values of 0.48 nm compared to 0.63 nm for unbound IGF1, alongside favorable free energy profiles and stable hydrogen bonding. These computational insights were strongly supported by in vitro experiments.
In vitro studies demonstrated a significant downregulation of
IGF1mRNA expression (p < 0.001) and a dose-dependent inhibition ofIGF1activity by Quercetin in AGS gastric cancer cells.
Key Findings
- Network pharmacology identified
IGF1as a key hub gene in gastric cancer progression. - Molecular docking predicted favorable binding of Quercetin to
IGF1with a score of -6.3 kcal/mol. MDsimulations confirmed the stability of the Quercetin-IGF1complex, showing reducedRMSDvalues (0.48 nm vs 0.63 nm).- Quercetin significantly downregulated
IGF1mRNA expression (p < 0.001) in gastric cancer cells. - Quercetin dose-dependently inhibited
IGF1activity in AGS gastric cancer cells.
Why It Matters
This study provides compelling evidence that Quercetin can directly modulate the IGF1 signaling axis in gastric cancer, offering a promising natural compound for therapeutic intervention. Targeting IGF1 with Quercetin could provide a less toxic alternative or adjuvant therapy to conventional treatments, potentially overcoming issues of drug resistance. While currently in vitro and computational, these findings lay the groundwork for future in vivo and clinical studies. For biohackers and those exploring natural compounds, this research highlights Quercetin's specific mechanism of action against a critical cancer pathway, suggesting its potential role in cancer prevention or supportive care protocols, though human efficacy and optimal dosing remain to be determined.
quercetin
gastric-cancer
igf1
network-pharmacology
molecular-docking
in-vitro